-

Johnson & Johnson to Participate in the Citi’s 2025 Global Healthcare Conference

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Citi’s 2025 Global Healthcare Conference on Wednesday, December 3rd, 2025. Management will participate in a Fireside Chat at 11:15 a.m. Eastern Time.

A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day.

The audio webcast replay will be available approximately 48 hours after the webcast.

Contacts

Johnson & Johnson

NYSE:JNJ

Release Versions

Contacts

More News From Johnson & Johnson

Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd, 2026. Management will participate in a Fireside Chat at 11:10 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available app...

Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson, with support from the Johnson & Johnson (J&J) Foundation, announced that it has donated $100 million of MedTech products since 2020 to help more people around the world access the specialized care they need to live, see and smile. The Company has also planned to contribute an additional $20 million toward programs and impact investments that empower health workers to deliver cardiac, vision and surgical care in their communiti...

Johnson & Johnson reports Q4 and Full-Year 2025 results

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. “2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: Oncology, Immunology, Neuros...
Back to Newsroom